| rs11612157 |
chr12 |
23698236 |
0.00084 |
C |
T |
Myopia (pathological) |
SOX5 |
intron |
21095009
|
| rs4246217 |
chr12 |
23698352 |
0.0000468 |
C |
T |
Multiple complex diseases |
SOX5 |
intron |
17554300
|
| rs4246218 |
chr12 |
23698387 |
0.000192 |
C |
G |
Multiple complex diseases |
SOX5 |
intron |
17554300
|
| rs4559766 |
chr12 |
23714022 |
0.000828 |
T |
C |
HIV-1 viral setpoint |
SOX5 |
intron |
17641165
|
| rs4559766 |
chr12 |
23714022 |
0.0000234 |
T |
C |
Orofacial clefts |
SOX5 |
intron |
20023658
|
| rs7972005 |
chr12 |
23725705 |
0.0000156 |
T |
G |
Platelet counts |
SOX5 |
intron |
pha003100
|
| rs10842183 |
chr12 |
23733442 |
0.0000000605 |
G |
A |
Corneal structure |
SOX5 |
intron |
22003120
|
| rs12231481 |
chr12 |
23739437 |
0.000595 |
C |
T |
Myopia (pathological) |
SOX5 |
intron |
21095009
|
| rs10771005 |
chr12 |
23744650 |
0.000391 |
G |
A |
Suicide attempts in bipolar disorder |
SOX5 |
intron |
21423239
|
| rs6487350 |
chr12 |
23746430 |
0.0000352 |
G |
A |
Hematocrit |
SOX5 |
intron |
pha003097
|
| rs16926452 |
chr12 |
23764620 |
0.000726 |
G |
A |
Multiple complex diseases |
SOX5 |
intron |
17554300
|
| rs10505896 |
chr12 |
23770330 |
0.000651 |
T |
C |
Multiple complex diseases |
SOX5 |
intron |
17554300
|
| rs10505899 |
chr12 |
23793205 |
0.00004 |
G |
A |
Rheumatoid Arthritis (Cyclic citrullinated peptide positive) |
SOX5 |
intron |
17982456
|
| rs973588 |
chr12 |
23828139 |
0.000885 |
T |
C |
Type 2 diabetes |
SOX5 |
intron |
17463246
|
| rs1382826 |
chr12 |
23859015 |
0.000568 |
A |
G |
Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) |
SOX5 |
intron |
20877124
|
| rs10771021 |
chr12 |
23875372 |
0.000364 |
T |
C |
Oral cancers (chewing tobacco related) |
SOX5 |
intron |
22503698
|
| rs7295342 |
chr12 |
23879554 |
0.000883 |
A |
G |
Oral cancers (chewing tobacco related) |
SOX5 |
intron |
22503698
|
| rs7295342 |
chr12 |
23879554 |
0.0000194 |
A |
G |
Amyotrophic lateral sclerosis (sporadic) |
SOX5 |
intron |
24529757
|
| rs10505904 |
chr12 |
23884513 |
0.0000753 |
G |
A |
Body Mass Index |
SOX5 |
intron |
pha003021
|
| rs4432100 |
chr12 |
23936823 |
0.000158 |
C |
T |
Multiple complex diseases |
SOX5 |
intron |
17554300
|
| rs4362223 |
chr12 |
23937856 |
0.0000969 |
A |
G |
Adipocyte fatty acid-binding protein concentration,in serum |
SOX5 |
intron |
21863005
|
| rs11047102 |
chr12 |
23946146 |
0.000138 |
C |
T |
Type 2 diabetes |
SOX5 |
intron |
17463246
|
| rs11047102 |
chr12 |
23946146 |
0.0000001 |
C |
T |
Systemic sclerosis |
SOX5 |
intron |
21779181
|
| rs11047102 |
chr12 |
23946146 |
0.000005 |
C |
T |
Systemic sclerosis |
SOX5 |
intron |
21779181
|
| rs11047102 |
chr12 |
23946146 |
0.000036 |
C |
T |
Breast cancer |
SOX5 |
intron |
23555315
|
| rs16926727 |
chr12 |
23952345 |
0.000472 |
A |
G |
Lung function (forced expiratory volume in 1 second) |
SOX5 |
intron |
24023788
|
| rs9804956 |
chr12 |
23981788 |
0.0000312 |
C |
T |
Asthma |
SOX5 |
intron |
23181788
|
| rs10505911 |
chr12 |
24022160 |
0.000556724 |
C |
A |
Hypertension (early onset hypertension) |
SOX5 |
intron |
22479346
|
| rs7136898 |
chr12 |
24054572 |
0.0000132 |
G |
T |
Multiple complex diseases |
SOX5 |
intron |
17554300
|
| rs4581551 |
chr12 |
24057198 |
0.000288347 |
C |
T |
Hypertension (early onset hypertension) |
SOX5 |
intron |
22479346
|
| rs3925064 |
chr12 |
24093764 |
0.00042 |
T |
C |
Pulmonary function |
SOX5 |
intron |
23932459
|
| rs11047179 |
chr12 |
24122931 |
0.000424 |
C |
T |
Alcohol dependence |
SOX5 |
intron |
24277619
|
| rs11830218 |
chr12 |
24124745 |
0.000173 |
G |
A |
Trunk whole body fat mass |
SOX5 |
intron |
23436924
|
| rs4480631 |
chr12 |
24125775 |
0.00068 |
T |
C |
Obesity (extreme) |
SOX5 |
intron |
21935397
|
| rs12229376 |
chr12 |
24129436 |
0.000935 |
G |
T |
Alcohol dependence |
SOX5 |
intron |
24277619
|
| rs11047188 |
chr12 |
24134126 |
0.000859 |
T |
C |
Obesity (extreme) |
SOX5 |
intron |
21935397
|
| rs17401403 |
chr12 |
24135271 |
0.00005 |
A |
G |
Prostate cancer |
SOX5 |
intron |
21743057
|
| rs11047189 |
chr12 |
24138764 |
0.000588 |
G |
T |
Obesity (extreme) |
SOX5 |
intron |
21935397
|
| rs10505921 |
chr12 |
24139829 |
0.000572 |
A |
G |
Obesity (extreme) |
SOX5 |
intron |
21935397
|
| rs1391781 |
chr12 |
24140100 |
0.000896 |
C |
T |
Obesity (extreme) |
SOX5 |
intron |
21935397
|
| rs1498869 |
chr12 |
24166453 |
0.000406 |
T |
C |
Alzheimer's disease |
SOX5 |
intron |
22005930
|
| rs6487369 |
chr12 |
24170019 |
0.0001 |
G |
A |
Cognitive impairment induced by topiramate |
SOX5 |
intron |
22091778
|
| rs4963737 |
chr12 |
24172215 |
0.0000143 |
T |
C |
Lupus nephritis in systemic lupus erythematosus |
SOX5 |
intron |
24925725
|
| rs17481181 |
chr12 |
24172546 |
0.00000012 |
T |
G |
Urinary metabolites |
SOX5 |
intron |
21572414
|
| rs17481181 |
chr12 |
24172546 |
0.0000143 |
T |
G |
Lupus nephritis in systemic lupus erythematosus |
SOX5 |
intron |
24925725
|
| rs7973213 |
chr12 |
24176297 |
0.0000137 |
C |
T |
Lupus nephritis in systemic lupus erythematosus |
SOX5 |
intron |
24925725
|
| rs12823336 |
chr12 |
24177194 |
0.0000138 |
T |
C |
Lupus nephritis in systemic lupus erythematosus |
SOX5 |
intron |
24925725
|
| rs17403340 |
chr12 |
24177880 |
0.0000141 |
T |
C |
Lupus nephritis in systemic lupus erythematosus |
SOX5 |
intron |
24925725
|
| rs10505927 |
chr12 |
24179673 |
0.0000167 |
G |
A |
Lupus nephritis in systemic lupus erythematosus |
SOX5 |
intron |
24925725
|
| rs7307316 |
chr12 |
24181408 |
0.000014 |
A |
G |
Lupus nephritis in systemic lupus erythematosus |
SOX5 |
intron |
24925725
|
| rs1909351 |
chr12 |
24182848 |
0.0000000889 |
C |
T |
Non-obstructive azoospermia |
SOX5 |
intron |
22197933
|
| rs10842262 |
chr12 |
24184544 |
0.000000002 |
G |
C |
Non-obstructive azoospermia |
SOX5 |
intron |
22197933
|
| rs1039229 |
chr12 |
24185520 |
0.0000000272 |
T |
C |
Non-obstructive azoospermia |
SOX5 |
intron |
22197933
|
| rs4963738 |
chr12 |
24190602 |
0.0000013 |
T |
C |
Urinary metabolites |
SOX5 |
intron |
21572414
|
| rs1353793 |
chr12 |
24190988 |
0.000072 |
T |
G |
stroke (ischemic) |
SOX5 |
intron |
17434096
|
| rs11047222 |
chr12 |
24192044 |
0.000714 |
A |
G |
Alzheimer's disease |
SOX5 |
intron |
22005930
|
| rs10505931 |
chr12 |
24194795 |
0.000629 |
T |
C |
Parkinson's disease |
SOX5 |
intron |
17052657
|
| rs11047225 |
chr12 |
24195587 |
0.000353 |
C |
T |
Alzheimer's disease |
SOX5 |
intron |
22005930
|
| rs7966115 |
chr12 |
24199202 |
0.000284 |
C |
T |
Alzheimer's disease |
SOX5 |
intron |
22005930
|
| rs7966115 |
chr12 |
24199202 |
0.000736 |
C |
T |
Response to taxane treatment (placlitaxel) |
SOX5 |
intron |
23006423
|
| rs11047240 |
chr12 |
24208478 |
0.000135 |
A |
G |
Multiple complex diseases |
SOX5 |
intron |
17554300
|
| rs7958678 |
chr12 |
24211259 |
0.0001 |
T |
C |
Cognitive impairment induced by topiramate |
SOX5 |
intron |
22091778
|
| rs4963564 |
chr12 |
24214050 |
0.0000456 |
C |
T |
Lupus nephritis in systemic lupus erythematosus |
SOX5 |
intron |
24925725
|
| rs4963565 |
chr12 |
24214258 |
0.00000026 |
A |
G |
Urinary metabolites |
SOX5 |
intron |
21572414
|
| rs4963565 |
chr12 |
24214258 |
0.0000451 |
A |
G |
Lupus nephritis in systemic lupus erythematosus |
SOX5 |
intron |
24925725
|
| rs12810574 |
chr12 |
24214665 |
0.0000452 |
C |
T |
Lupus nephritis in systemic lupus erythematosus |
SOX5 |
intron |
24925725
|
| rs17485232 |
chr12 |
24215026 |
0.0000447 |
T |
C |
Lupus nephritis in systemic lupus erythematosus |
SOX5 |
intron |
24925725
|
| rs10505932 |
chr12 |
24237747 |
0.0000661 |
T |
G |
QT interval |
SOX5 |
intron |
16648850
|
| rs17407659 |
chr12 |
24238010 |
0.000025 |
C |
T |
Lupus nephritis in systemic lupus erythematosus |
SOX5 |
intron |
24925725
|
| rs10505936 |
chr12 |
24273423 |
0.000493 |
G |
A |
White matter integrity |
SOX5 |
intron |
22425255
|
| rs7139049 |
chr12 |
24273754 |
0.000388 |
G |
T |
Taste perception |
SOX5 |
intron |
22132133
|
| rs2030130 |
chr12 |
24274071 |
0.000004 |
C |
T |
Response to statin therapy |
SOX5 |
intron |
20339536
|
| rs2030129 |
chr12 |
24275387 |
0.0000025 |
C |
G |
Response to statin therapy |
SOX5 |
intron |
20339536
|
| rs7979575 |
chr12 |
24278821 |
0.000002 |
C |
G,T |
Response to statin therapy |
SOX5 |
intron |
20339536
|
| rs10842277 |
chr12 |
24280870 |
0.000654 |
T |
A |
Multiple complex diseases |
SOX5 |
intron |
17554300
|
| rs11047279 |
chr12 |
24293302 |
0.00007 |
C |
T |
Alcohol and nictotine co-dependence |
SOX5 |
intron |
20158304
|
| rs11047279 |
chr12 |
24293302 |
0.000706 |
C |
T |
Myopia (pathological) |
SOX5 |
intron |
21095009
|
| rs10734733 |
chr12 |
24294258 |
0.000491 |
T |
C |
Myopia (pathological) |
SOX5 |
intron |
21095009
|
| rs10082842 |
chr12 |
24300902 |
0.0000301 |
T |
C |
Amyotrophic lateral sclerosis |
SOX5 |
intron |
20801718
|
| rs16927285 |
chr12 |
24326382 |
0.000938 |
A |
G |
Multiple complex diseases |
SOX5 |
intron |
17554300
|
| rs10842292 |
chr12 |
24348317 |
0.000027 |
C |
A |
Urinary metabolites |
SOX5 |
intron |
21572414
|
| rs12581837 |
chr12 |
24358253 |
0.000327 |
T |
C |
Blood pressure |
SOX5 |
intron |
17255346
|
| rs3922562 |
chr12 |
24358865 |
0.0000592 |
C |
T |
Body Mass Index |
SOX5 |
intron |
pha003020
|
| rs1357251 |
chr12 |
24375601 |
0.000765 |
T |
C |
Alcohol dependence |
SOX5 |
intron |
20201924
|
| rs11047323 |
chr12 |
24384154 |
0.000829 |
A |
G |
Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) |
SOX5 |
intron |
20877124
|
| rs1464502 |
chr12 |
24388089 |
0.000522 |
A |
G |
Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) |
SOX5 |
intron |
20877124
|
| rs1464500 |
chr12 |
24389660 |
0.0000001 |
G |
T |
Response to antipsychotic treatment |
SOX5 |
intron |
20195266
|
| rs884440 |
chr12 |
24392816 |
0.0000177 |
G |
A |
Psoriasis |
SOX5 |
intron |
18364390
|
| rs1522232 |
chr12 |
24394372 |
0.000002 |
T |
C |
AIDS |
SOX5 |
intron |
19754311
|
| rs2686331 |
chr12 |
24403997 |
0.000315 |
A |
C |
Systemic lupus erythematosus and Systemic sclerosis |
SOX5 |
intron |
23740937
|
| rs10505939 |
chr12 |
24447034 |
0.000122 |
T |
C |
Smoking initiation |
SOX5 |
intron |
24665060
|
| rs1522228 |
chr12 |
24453707 |
0.000565 |
C |
T |
HIV-1 viral setpoint |
SOX5 |
intron |
17641165
|
| rs11047359 |
chr12 |
24457216 |
0.000495 |
G |
A |
Multiple complex diseases |
SOX5 |
intron |
17554300
|
| rs7978406 |
chr12 |
24466704 |
0.000644 |
C |
G |
Insulin resistance |
SOX5 |
intron |
21901158
|
| rs11616084 |
chr12 |
24467149 |
0.000348 |
T |
C |
Insulin resistance |
SOX5 |
intron |
21901158
|
| rs579556 |
chr12 |
24471760 |
0.0004 |
C |
T |
Multiple complex diseases |
SOX5 |
intron |
17554300
|
| rs953334 |
chr12 |
24471815 |
0.00093 |
C |
T |
Multiple complex diseases |
SOX5 |
intron |
17554300
|
| rs953334 |
chr12 |
24471815 |
0.000101 |
C |
T |
Insulin resistance |
SOX5 |
intron |
21901158
|
| rs7980156 |
chr12 |
24475862 |
0.000154 |
T |
G |
Insulin resistance |
SOX5 |
intron |
21901158
|
| rs563776 |
chr12 |
24479206 |
0.000529 |
C |
A |
Multiple complex diseases |
SOX5 |
intron |
17554300
|
| rs472100 |
chr12 |
24479494 |
0.0000209 |
C |
T |
Anxiety and major depressive disorder |
SOX5 |
intron |
24047446
|
| rs2055731 |
chr12 |
24482034 |
0.000522459 |
C |
T |
Hypertension (early onset hypertension) |
SOX5 |
intron |
22479346
|
| rs550338 |
chr12 |
24512037 |
0.00022 |
G |
A |
Alcohol dependence |
SOX5 |
intron |
20201924
|
| rs550338 |
chr12 |
24512037 |
0.000089 |
G |
A |
Alcohol dependence |
SOX5 |
intron |
20201924
|
| rs550338 |
chr12 |
24512037 |
0.0000888 |
G |
A |
Alcoholism |
SOX5 |
intron |
pha002893
|
| rs7968811 |
chr12 |
24536837 |
0.00028 |
C |
T |
Pulmonary function |
SOX5 |
intron |
23932459
|
| rs7966399 |
chr12 |
24551705 |
0.000944 |
A |
G |
Methotrexate clearance (acute lymphoblastic leukemia) |
SOX5 |
intron |
23233662
|
| rs4963756 |
chr12 |
24553387 |
0.00096 |
G |
A |
Methotrexate clearance (acute lymphoblastic leukemia) |
SOX5 |
intron |
23233662
|
| rs11047417 |
chr12 |
24555441 |
0.000586 |
T |
C |
Oral cancers (chewing tobacco related) |
SOX5 |
intron |
22503698
|
| rs17417768 |
chr12 |
24558745 |
0.0000115 |
T |
C |
Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) |
SOX5 |
intron |
25044411
|
| rs10743498 |
chr12 |
24559370 |
0.000173 |
T |
C |
Type 2 diabetes |
SOX5 |
intron |
17463246
|
| rs10743498 |
chr12 |
24559370 |
0.0005609 |
T |
C |
Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) |
SOX5 |
intron |
23233654
|
| rs10743498 |
chr12 |
24559370 |
0.000561 |
T |
C |
Methotrexate clearance (acute lymphoblastic leukemia) |
SOX5 |
intron |
23233662
|
| rs7309268 |
chr12 |
24560244 |
0.000964 |
G |
T |
Alcohol dependence |
SOX5 |
intron |
21314694
|
| rs11047424 |
chr12 |
24560842 |
0.0000744 |
G |
A |
Serum metabolites |
SOX5 |
intron |
19043545
|
| rs11047425 |
chr12 |
24560894 |
0.00003261 |
C |
G |
Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) |
SOX5 |
intron |
23233654
|
| rs11047425 |
chr12 |
24560894 |
0.000951 |
C |
G |
Methotrexate clearance (acute lymphoblastic leukemia) |
SOX5 |
intron |
23233662
|
| rs17509005 |
chr12 |
24576205 |
0.000396 |
T |
C |
Multiple complex diseases |
SOX5 |
intron |
17554300
|
| rs11047431 |
chr12 |
24578520 |
0.000872 |
A |
G |
Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) |
SOX5 |
intron |
23233654
|
| rs11047431 |
chr12 |
24578520 |
0.000872 |
A |
G |
Methotrexate clearance (acute lymphoblastic leukemia) |
SOX5 |
intron |
23233662
|
| rs10505940 |
chr12 |
24581756 |
0.0000108 |
T |
C |
Body Mass Index |
SOX5 |
intron |
pha003014
|
| rs1396200 |
chr12 |
24613747 |
0.0000113 |
C |
T |
Calcium levels |
SOX5 |
intron |
pha003085
|
| rs11047458 |
chr12 |
24614105 |
0.0007523 |
A |
G |
Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) |
SOX5 |
intron |
23233654
|
| rs11047458 |
chr12 |
24614105 |
0.000752 |
A |
G |
Methotrexate clearance (acute lymphoblastic leukemia) |
SOX5 |
intron |
23233662
|
| rs11047461 |
chr12 |
24618042 |
0.0000632 |
C |
T |
Body Mass Index |
SOX5 |
intron |
pha003014
|
| rs7969711 |
chr12 |
24619507 |
0.0000277 |
C |
T |
Body Mass Index |
SOX5 |
intron |
pha003014
|
| rs10842357 |
chr12 |
24628433 |
0.000652 |
T |
G |
Multiple complex diseases |
SOX5 |
intron |
17554300
|
| rs4963767 |
chr12 |
24653672 |
0.0000621 |
C |
T |
Response to cytadine analogues (cytosine arabinoside) |
SOX5 |
intron |
24483146
|
| rs4963768 |
chr12 |
24654276 |
0.0000712 |
G |
A |
Response to cytadine analogues (cytosine arabinoside) |
SOX5 |
intron |
24483146
|
| rs4963768 |
chr12 |
24654276 |
0.0000344 |
G |
A |
Left ventricular hypertrophy |
SOX5 |
intron |
pha003052
|
| rs17284897 |
chr12 |
24672026 |
0.0000577 |
C |
T |
Lipid levels |
SOX5 |
intron |
pha003082
|
| rs7295669 |
chr12 |
24701792 |
0.00023 |
T |
C |
Multiple complex diseases |
SOX5 |
intron |
17554300
|
| rs16927697 |
chr12 |
24704498 |
0.000365 |
A |
G |
Smoking quantity |
SOX5 |
intron |
24665060
|